Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Clin Gastroenterol Hepatol. 2022 Sep;20(9):2145-2147.e2. doi: 10.1016/j.cgh.2022.04.006. Epub 2022 Apr 26.
Patients suffering from autoimmune hepatitis, a chronic immune-mediated liver disease with an incidence of 0.9 to 2 per 100,000 population per year in Europe, are considered to have a particularly increased risk for coronavirus disease 2019 (Covid-19)-associated hospitalization and death. Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccination provides an essential tool to reduce morbidity and mortality in this cohort. However, a large multicenter study in China has shown a lower immunogenic response to inactivated whole-virion SARS-CoV-2 vaccines of chronic liver disease patients in comparison with the healthy population. Furthermore, reports from inflammatory bowel diseases or rheumatic disorders showed a reduced serologic response in patients taking glucocorticoids or thiopurine. The decrease in vaccine-induced antibodies over time, as well as the emergence of variants of concern, led to the recommendation of an additional vaccination in immunocompromised patients.
患有自身免疫性肝炎的患者被认为具有较高的 2019 冠状病毒病（COVID-19）相关住院和死亡风险，该病是一种慢性免疫介导的肝脏疾病，在欧洲的年发病率为每 10 万人中有 0.9 至 2 人。严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）疫苗接种为降低该人群的发病率和死亡率提供了重要工具。然而，中国的一项大型多中心研究表明，与健康人群相比，慢性肝病患者对灭活全病毒 SARS-CoV-2 疫苗的免疫原性反应较低。此外，来自炎症性肠病或风湿性疾病的报告显示，服用糖皮质激素或硫嘌呤的患者血清学反应降低。随着时间的推移，疫苗诱导的抗体减少以及关注变体的出现，导致建议免疫功能低下的患者进行额外的疫苗接种。
